Schmeling, Heinrike <br/><br/>
Efficacy and safety of adalimumab as the first and second biologic agent in juvenile idiopathic arthritis: the German Biologics JIA Registry.  [electronic resource] 

 -  Arthritis & rheumatology (Hoboken, N.J.)  Sep 2014 
 - 2580-9 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>2326-5205 
<br/><br/><label>Standard No.: </label>10.1002/art.38741  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adalimumab<br/>Adolescent<br/>Antibodies, Monoclonal, Humanized--adverse effects<br/>Antirheumatic Agents--adverse effects<br/>Arthritis, Juvenile--drug therapy<br/>Biological Products--adverse effects<br/>Child<br/>Female<br/>Germany<br/>Humans<br/>Male<br/>Registries<br/>Severity of Illness Index<br/>Treatment Outcome